Utilizzo delle linee-guida nella diagnostica di laboratorio delle dislipidemie: risultati di un’indagine nei laboratori italiani

AUTORI

ABSTRACT

Adherence to guidelines in the laboratory evaluation of dyslipidemias: results of a survey from italian clinical laboratories

Background: the poor adherence to guidelines approved by scientific societies are widely described as a possible cause of criticisms in the management of several diseases. In the setting of dyslipidemia, a lack of compliance with clinical and biochemical recommendations defining the informations that should be included in the laboratory report, could be a relevant issue.
Methods: in order to verify the state-of-the art of this specific topic, a survey containing 8 questions spanning from the pre-analitycal phase (panel of tests, nonfasting testing), to analytical (types of methods and equations) and to post-analytical phase (reference interval, desirable values, therapeutic goals) was sent to the laboratory professionals registered in the Italian Society of Clinical Biochemistry and Molecular Biology (SIBioC).
Results: the most interesting results demonstrate that: about 40% of the laboratories add to the traditional lipid panels (total, LDL and HDL cholesterol, tryglicerides) the recommended measurement of apolipoproteins (Apo-A1, Apo-B and Lpa); 89% adopt the fasting testing; 73.6% use direct methods to measure HDL-C and 29% calculate LDL-C using Friedewald equation; 87.3% of the values are reported using the traditional (mg/dL) units; 64.5% use the reference interval as comparator, inadequate for the most part of lipid tests, 51.4% desirable levels, only 5.61% the recommended therapeutic goals.
Discussion: on the basis of the obtained data, a shared improvement in the adoption and application of the recommendations published by SIBioC but poorly adopted until now, seems to be a fundamental activity that should be undertaken in the near future.

BIBLIOGRAFIA

Plebani M. Adherence to recommendations and clinical practice guidelines: not an easy task. Clin Chem Lab Med 2023;61:2065-66.

Barth JH, Misra S, Aakre KM, Langlois MR, Watine J, Twomey PJ et al. Why are clinical practice guidelines not followed? Clin Chem Lab Med 2016;54:1133-9.

Cadamuro J, Hillarp A, Unger A, von Meyer A, Bauçà JM, Plekhanova O et al. Presentation and formatting of laboratory results: a narrative review on behalf of the European Federation of Clinical Chemistry and Laboratory Medicine (EFLM) Working Group “postanalytical phase” (WG-POST). Crit Rev Clin Lab Sci 2021;58:329-53.

Plebani M. Harmonization in laboratory medicine: Requests, samples, measurements and reports. Crit Rev Clin Lab Sci 2016;53:184-96.

Langlois MR, Nordestgaard BG, Langsted A, Kamstrup PR, Chapman MJ, Aakre KM et al. Quantificazione delle lipoproteine aterogeniche per le terapie lipolipemizzanti: Raccomandazioni di Consenso della European Atherosclerosis Society (EAS) e di EFLM. Biochim Clin 2020;44:290-313.

Graziani MS, Ceriotti F, Zaninotto M, Catapano AL, Medea G, Parretti D et al. La diagnostica di laboratorio delle dislipidemie. Documento di consenso SIBioC- Medicina di Laboratorio, Società Italiana per lo Studio dell’Aterosclerosi (SISA), Società Italiani di Medicina Generale (SIMG) e Associazione Nazionale Medici Cardiologi Ospedalieri (ANMCO). Biochim Clin 2016;40:338-46.

Catapano AL, Franzini C, Galli G, Graziani MS, Lippi U, Notarbartolo A et al. Linee-guida per la refertazione dei lipidi plasmatici e delle lipoproteine. Gruppo di lavoro Intersocietario SIBioC, SIMeL, SISA. Biochim Clin 2001;25:283-8.

Mach F, Baigent C, Catapano AL, Koskinas KC, Casula M, Badimon L et al. 2019 ESC/EAS guidelines for the management of dyslipidemias: lipid modification to reduce cardiovascular risk. The Task Force for the management of dyslipidemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS). Eur Heart J 2020;41:111-88.

Conroy RM, Pyorala K, Fitzgerald AP, Sans S, Menotti A, De Backer G et al. Estimation of ten-year risk of fatal cardiovascular disease in Europe: The SCORE project. Eur Heart J 2003; 24:987-1003.

Morieri ML, Perrone V, Veronesi C, Degli Espositi L, Andretta M, Plebani M et al. Improving statin treatment strategies to reduce LDL-cholesterol: factors associated with targets’ attainment in subjects with and without type 2 diabetes. Cardivasc Diabetol 2021;20:144

Marcusa DP, Giugliano RP, Park JG, de Lemos JA, Cannon CP, Sabatine MS. Association of baseline Low Density Lipoprotein Cholesterol and percentage Low-Density Cholesterol reduction with Statins, Ezetimibe, and PCSK9 inhibition. JAMA Cardiol 2021;65:582-6.

Schulte C, Zeller T. Biomarkers in primary prevention. Meaningful diagnosis based on biomarkers score? Herz 2020;45:10-6.

Nordestgaard BG, Langsted A, Mora S, Kolovou G, Baum H, Bruckert E et al. Fasting is not routinely required for determination of a lipid profile: clinical and laboratory implications including flagging at desirable concentration cut-points. A joint consensus statement from the EAS and EFLM. Eur Heart J 2016;37:1944-58.

Farukhi Z, Mora S. Nonfasting lipids for all patients? Clin Chem 2020;6:41-5.

Foraison NC, Marcovina SM, Guerra E, Aarsand AK, Coskun A, Diaz-Garzon J et al. Analytical performance for lipoprotein (a), apolipoprotein B-100 and apolipoprotein A1 using the biological variation model in the EuBIVAS population. Clin Chem 2020;66:727-36.

Wyness SP, Genzen JR. Performance evaluation of five lipoprotein (a) immunoassays on the Roche cobas c501 chemistry analyzer. Pract Lab Med 2021;25:e00218.

Martin SS, Blaha MJ, Elshazly MB, Toth PP. Comparison of a novel method vs the Friedewald Equation for estimating Low-Density Lipoprotein Cholesterol levels from the standard lipid profile. JAMA 2013;310:2061-8.

Cartier LJ, St-Coeur S, Robin A, Lagace M, Douville P. Impact of the Martin/Hopkins modified equation for estimating LDL-C on lipid target attainment in an high risk patient population. Clin Biochem 2020;76:35-7.

AAVV. SIBioC 2023 Strategic Conference. Il futuro della Medicina di Laboratorio. Biochim Clin 2023;47 Suppl2.

Lloyd-Jones DM, Allen NB, Anderson CAM, Black T, Brewer LPC, Foraker RE et al. Life’s essential8: updating and enhancing the American Heart Association’s construct of cardiovascular health: a Presidential Advisory from the American Heart Association. Circulation 2022;146:e18-e43.

Marston NA, Giugliano MD, Melloni GEM, Park JG, Mottill V, Blazing MA. Association of Apolipoprotein B-Containing lipoproteins and risk of myocardial infarction in individuals with and without atherosclerosis. Distinguishing between particle concentration, type and content. JAMA Cardiol 2022;7:250-6.

Sniderman AD, Navar AM, Thanassoulis GT. Apolipoprotein B vs Low-density lipoprotein Cholesterol and Non-High Density Lipoprotein Cholesterol as the primary measure of Apolipoprotein B Lipoprotein-related risk. JAMA Cardiol 2022;7:257-8.

Diederiks NM, van der Burgt YEM, Ruhaak LR, Cobbaert CM. Developing an SI-traceable Lpa reference measurement system: a pilgrimage to selective and accurate Apo A quantification. Crit Rev Clin Lab Sci 2023;60:483-501.